Orismilast
- Generic Name
- Orismilast
Robust Pipeline of 50+ Therapies Reshaping Moderate to Severe Atopic Dermatitis Treatment Landscape
• The moderate to severe atopic dermatitis market is experiencing significant growth with 45+ companies developing over 50 pipeline therapies, driven by rising global prevalence and increased awareness of the condition.
• Recent advancements include promising biologics like rezpegaldesleukin (granted FDA fast-track designation), JAK inhibitors such as VC005 and QY201, and novel mechanisms targeting IL-4/IL-13 pathways, offering new hope for patients with inadequate response to current treatments.
• Key players including Nektar Therapeutics, Corvus Pharmaceuticals, and Apogee Therapeutics are advancing clinical trials with significant milestones expected in late 2025, potentially transforming the therapeutic landscape for this chronic inflammatory skin condition.
Hidradenitis Suppurativa: Advances in Treatment and Research Highlighted in 2024
• Bimekizumab gains EU approval and FDA acceptance for HS treatment based on Phase 3 BE HEARD trials, demonstrating significant improvements in skin pain.
• Lutikizumab shows positive Phase 2 results, including in patients who failed TNF therapy, and advances to Phase 3 trials for HS treatment.
• Research indicates potential benefits of oral orismilast and intravenous ertapenem in managing HS, alongside dietary considerations and surgical procedures.
Union Therapeutics Advances Orismilast to Phase III for Atopic Dermatitis After Positive Phase IIb Results
• Union Therapeutics plans to initiate a Phase III trial for orismilast in atopic dermatitis following successful Phase IIb results.
• The Phase IIb ADESOS trial demonstrated a significant reduction in eczema area and severity index (EASI) scores with orismilast.
• Orismilast, a PDE4 inhibitor, showed promising results across multiple inflammatory indications, including psoriasis and hidradenitis suppurativa.
• The treatment groups also experienced a notable reduction in CCL17/TARC skin levels, a key biomarker for atopic dermatitis.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath